Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 23
Filter
Add more filters











Publication year range
1.
Arch Dermatol Res ; 315(1): 51-59, 2023 Jan.
Article in English | MEDLINE | ID: mdl-35059802

ABSTRACT

Basal cell carcinoma (BCC) data coming from the Levantine coast of the Mediterranean Sea are limited. The study aimed to primarily analyze the demographic, clinical, pathological, and prognostic characteristics of BCC in this region of the world and secondarily identify features associated with high-risk, recurrent, or multiple BCCs. Patients with at least one diagnosis of BCC registered in the pathology department between January 2015 and December 2019 were included in this analytical retrospective single-center cohort study. Patients with basal cell nevus syndrome were excluded. Patients' characteristics and pathological features were collected through file check for a first analysis. Risk factors and evolution were sought through a phone call interview for the second analysis. The first analysis included 506 BCCs corresponding to 365 patients with a mean age of 65 ± 15 years, twenty-two (6%) were less than 40 years old, 180 (49.3%) were women, and 85 (23.3%) had two or more BCCs. The second analysis included 279 BCCs corresponding to 205 patients. Periorificial and infiltrative BCCs were more frequent in men. Periorificial tumors were more frequently nodular or infiltrative and were associated with recurrence. Tumors with perineural involvement were histologically never nodular nor superficial. Recurrence was more frequent in BCCs having periorificial location, a size larger than 2 cm, or an infiltrative subtype. Multiple BCCs were more frequent in patients with light skin type or familial history of skin cancer. High-risk BCCs were more common in patients with low sun exposure.


Subject(s)
Carcinoma, Basal Cell , Skin Neoplasms , Male , Humans , Female , Middle Aged , Aged , Aged, 80 and over , Adult , Retrospective Studies , Cohort Studies , Mediterranean Sea , Carcinoma, Basal Cell/pathology , Skin Neoplasms/pathology
3.
Anticancer Drugs ; 34(1): 187-189, 2023 01 01.
Article in English | MEDLINE | ID: mdl-36539371

ABSTRACT

EGFR inhibitors used in the treatment of metastatic wild-RAS colorectal cancer in combination with chemotherapy are associated with dermatologic side events that are low grade in most cases. We report a case of severe cutaneous toxicity secondary to cetuximab associated with bacterial cellulitis. A 57-year-old woman with metastatic adenocarcinoma of the colon, receiving FOLFIRI and Cetuximab as a first-line treatment, presented with a severe erythematous rash and xerosis resistant to local treatment with moisturizing emollients. Few days later, the patient becomes febrile, and the rash becomes more diffuse with a sandpaper appearance on the face, neck, chest, and flexor creases with exfoliation of large areas of skin. A bacterial cellulitis secondary to a dermatologic severe toxicity of Cetuximab was suspected. The patient started on antibiotics and local treatment with good response. This is a life-threatening cutaneous toxicity of cetuximab with secondary bacterial infection. Early recognition of cutaneous side effects of EGFR inhibitors is important to prevent such type of toxicities.


Subject(s)
Bacteremia , Colorectal Neoplasms , Drug Eruptions , Exanthema , Skin Diseases , Female , Humans , Middle Aged , Cetuximab/adverse effects , Antibodies, Monoclonal , Cellulitis/chemically induced , Cellulitis/drug therapy , Drug Eruptions/drug therapy , Drug Eruptions/etiology , Drug Eruptions/prevention & control , Colorectal Neoplasms/pathology , Skin Diseases/chemically induced , Exanthema/chemically induced , Exanthema/drug therapy , ErbB Receptors , Bacteremia/chemically induced , Bacteremia/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Fluorouracil/therapeutic use , Leucovorin/therapeutic use
6.
Int J Womens Dermatol ; 7(4): 415-421, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34621953

ABSTRACT

BACKGROUND: Acne is highly prevalent among teenagers and young adults, with proven negative psychological and emotional impact. To our knowledge, no study has been conducted to quantify the repercussions of acne on quality of life (QoL) and self-esteem in Lebanon. OBJECTIVE: This study aimed to highlight the effect of acne treatment on QoL and self-esteem of Lebanese adolescents and young adults. METHODS: In this observational prospective study, patients between 15 and 40 years old with moderate-to-severe acne were allocated to one of two treatment groups (isotretinoin vs. systemic antibiotics combined with topical treatments) and followed for a period of 6 months. The effect of acne on QoL was measured using the Dermatology Life Quality Index, Cardiff Acne Disability Index, and Rosenberg Self-esteem Scale before treatment initiation (T1), after 3 months (T2), and after 6 months (T3). A multivariate analysis of covariance model was used. RESULTS: Sixty-two patients were included, of whom 79% were female and 61.3% had moderate acne. Fifty-five percent of patients were treated with systemic antibiotics combined with topical treatments, and 45% received isotretinoin. Mean scores of Cardiff Acne Disability Index, Dermatology Life Quality Index, and Rosenberg Self-esteem Scale at T1 were comparable between the two groups. A significant improvement was noticed in both groups at T2 and T3. The multivariate analysis of covariance model showed an interaction of time and age that concerned 25- to 40-year-old patients in both groups, who were the most negatively affected by acne at T1 and improved the most at T3. CONCLUSION: This study demonstrated the equivalence between acne treatments in improving QoL and revealed the social obstacle that acne creates and its recrudescence in the subgroup of women of childbearing age.

7.
Future Sci OA ; 7(6): FSO695, 2021 Mar 04.
Article in English | MEDLINE | ID: mdl-34046199

ABSTRACT

Gianotti-Crosti syndrome (GCS) is a self-limited benign dermatosis, clinically characterized by a monomorphic papular or papulovesicular eruption symmetrically distributed on the limbs and face of children. Various viral and vaccine triggers have been associated with GCS. Recurrences are uncommon but have been reported. We report a case of recurrent vaccine-triggered GCS.

8.
Dermatol Ther ; 33(6): e13985, 2020 11.
Article in English | MEDLINE | ID: mdl-32639071

ABSTRACT

A few studies discussed short outcomes in fractional CO2 laser. This study aimed to seek factors of medium-term efficacy and safety in patients treated for facial rejuvenation or acne scars. This single-center, prospective, single-arm, evaluator-blinded cohort study included patients of 18 years and older undergoing a fractional CO2 laser for facial skin rejuvenation or atrophic acne scars. One session of ultrapulsed fractional 10 600 nm CO2 laser was performed with the Deep FX TM mode in acne scars and the Active FX TM mode in facial rejuvenation and acne scars. Follow-up was carried out for 6 months. In the end, a patient self-satisfaction assessment was obtained. A blinded physician graded improvement based on pretreatment and 6-month photography. The study included 75 patients, of whom 88% were women. Forty-five had facial rejuvenation, and 30 had atrophic acne scars treatment. Half of the patients were satisfied. The physician-blinded evaluation indicated "good to very good" improvement in 46.7% of facial rejuvenation patients, and 30% of acne scars patients. Hyperpigmentation and folliculitis were recorded in 15 and 3 patients, respectively. This study did not find statistically significant factors to predict outcomes in a fractional CO2 laser. We could however note better results in acne scar patients of thicker skin, and facial rejuvenation patients of younger age and thinner skin. We counted more hyperpigmentation events in phototypes III and IV, and it was reversible in all cases.


Subject(s)
Acne Vulgaris , Lasers, Gas , Acne Vulgaris/complications , Acne Vulgaris/diagnosis , Carbon Dioxide , Cicatrix/etiology , Cicatrix/pathology , Cohort Studies , Female , Humans , Lasers, Gas/adverse effects , Male , Prospective Studies , Treatment Outcome
10.
Indian J Dermatol ; 61(4): 447-8, 2016.
Article in English | MEDLINE | ID: mdl-27512196
11.
Indian J Dermatol ; 61(2): 235, 2016.
Article in English | MEDLINE | ID: mdl-27057043

ABSTRACT

Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome or drug-induced hypersensitivity syndrome (DIHS) is a severe adverse drug reaction. It can present with clinical, paraclinical, and histological findings mimicking skin and/or systemic lymphomas. We report the first case of a lamotrigine-induced DRESS with histologic features of a cutaneous CD30+ lymphoma. The patient responded well to a tapering course of oral steroids. This case highlights the atypical presentation of a lamotrigine-induced DRESS/DIHS in the presence of a cutaneous and a lymph node CD30 + lymphocytic infiltrate mimicking systemic lymphoma. Pathologists and clinicians must be aware of this "lymphomatous" presentation of drug reactions.

13.
J Cosmet Laser Ther ; 18(1): 46-7, 2016.
Article in English | MEDLINE | ID: mdl-26052811

ABSTRACT

Skin grafts are widely used in reconstructive and plastic surgery, leaving an inevitable scar appearance on the body, affecting the quality of life of the patients. Fractional ablative lasers have become a leading procedure for the treatment of acne and burn scars. We report a case of a skin graft showing excellent improvement in overall appearance after three sessions of fractional CO2 laser. The undamaged tissue left between the microthermal treatment zones is responsible of collagen formation and reepithelialization. Remodeling and collagen formation are observed even 6 months after a fractional CO2 laser session.


Subject(s)
Cosmetic Techniques , Lasers, Gas/therapeutic use , Skin Transplantation , Ablation Techniques , Adult , Cicatrix/etiology , Cicatrix/surgery , Female , Humans , Skin Transplantation/adverse effects
14.
J Cosmet Dermatol ; 13(4): 346-8, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25399628

ABSTRACT

Botulinum toxin injections have become the most frequent noninvasive cosmetic procedure carried out worldwide. Botulinum toxin has also multiple other indications in different medical fields. However, with the repetition of injections, a new concern has emerged: clinical resistance and loss of effectiveness of the treatment. After reporting a case of primary nonresponsiveness to three types of botulinum toxin type A injections, we conducted a review about all factors leading to the primary or secondary nonresponsiveness, as well as the factors affecting the immunogenicity of this neurotoxin. Most of the reports and studies focused on secondary resistance to botulinum toxin (BT) and the neurotoxin immunogenicity; primary nonresponsiveness was rarely reported. Factors leading to primary or secondary resistance to BT injections were numerous. In the majority of the studies, development of neutralizing antibodies to botulinum toxin was considered responsible of the induced clinical resistance. Patients should be aware of this rising concern as well as clinicians who should learn how to minimize the risk of resistance development, sparing the patients more invasive treatment modalities. Further studies related to botulinum toxin resistance are needed.


Subject(s)
Botulinum Toxins, Type A/administration & dosage , Cosmetic Techniques , Neuromuscular Agents/administration & dosage , Skin Aging/drug effects , Antibodies, Neutralizing/immunology , Botulinum Toxins, Type A/immunology , Esthetics , Female , Humans , Middle Aged , Neuromuscular Agents/immunology , Treatment Failure
17.
J Cutan Aesthet Surg ; 6(1): 30-2, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23723602

ABSTRACT

BACKGROUND: Fractionated carbon dioxide (CO2) lasers are a new treatment modality for skin resurfacing. The cosmetic rejuvenation market abounds with various injectable devices (poly-L-lactic acid, polymethyl-methacrylate, collagens, hyaluronic acids, silicone). The objective of this study is to examine the efficacy and safety of 10,600-nm CO2 fractional laser on facial skin with previous volume injections. MATERIALS AND METHODS: This is a retrospective study including 14 patients treated with fractional CO2 laser and who have had previous facial volume restoration. The indication for the laser therapy, the age of the patients, previous facial volume restoration, and side effects were all recorded from their medical files. Objective assessments were made through clinical physician global assessment records and improvement scores records. Patients' satisfaction rates were also recorded. RESULTS: Review of medical records of the 14 patients show that five patients had polylactic acid injection prior to the laser session. Eight patients had hyaluronic acid injection prior to the laser session. Two patients had fat injection, two had silicone injection and one patient had facial thread lift. Side effects included pain during the laser treatment, post-treatment scaling, post-treatment erythema, hyperpigmentation which spontaneously resolved within a month. Concerning the previous facial volume restoration, no granulomatous reactions were noted, no facial shape deformation and no asymmetry were encountered whatever the facial volume product was. CONCLUSION: CO2 fractional laser treatments do not seem to affect facial skin which had previous facial volume restoration with polylactic acid for more than 6 years, hyaluronic acid for more than 0.5 year, silicone for more than 6 years, or fat for more than 1.4 year. Prospective larger studies focusing on many other variables (skin phototype, injected device type) are required to achieve better conclusions.

20.
Cutis ; 90(5): 256-7, 2012 Nov.
Article in English | MEDLINE | ID: mdl-23270198

ABSTRACT

Various treatment options are available for basal cell carcinoma (BCC). We report a case of a patient with a nodular BCC on the nose who was treated with combination therapy consisting of cryotherapy with liquid nitrogen followed by imiquimod cream 5% 5 times weekly for 6 weeks. Clearance of the lesion was histologically confirmed.


Subject(s)
Aminoquinolines/therapeutic use , Antineoplastic Agents/therapeutic use , Carcinoma, Basal Cell/therapy , Cryotherapy , Facial Neoplasms/therapy , Skin Neoplasms/therapy , Aged, 80 and over , Combined Modality Therapy , Humans , Imiquimod , Male , Nose
SELECTION OF CITATIONS
SEARCH DETAIL